The Comparative Effectiveness of Ciprofloxacin and Metronidazole for an Initial Episode of Pouchitis: A Propensity-Matched Study

被引:9
作者
Barnes, Edward L. [1 ,2 ,3 ]
Desai, Aakash [4 ]
Kochhar, Gursimran S. [5 ]
机构
[1] Univ North Carolina Chapel Hill, Div Gastroenterol & Hepatol, Chapel Hill, NC 27599 USA
[2] Univ North Carolina Chapel Hill, Multidisciplinary Ctr Inflammatory Bowel Dis, Chapel Hill, NC 27599 USA
[3] Univ North Carolina Chapel Hill, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC 27599 USA
[4] Case Western Reserve Univ, MetroHlth Med Ctr, Div Gastroenterol & Hepatol, Cleveland, OH USA
[5] Allegheny Hlth Network, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA
基金
美国国家卫生研究院;
关键词
comparative effectiveness; real-world effectiveness; pouchitis; ileal pouch-anal anastomosis; ILEAL-POUCH; ANAL-ANASTOMOSIS; DOUBLE-BLIND; CONSENSUS GUIDELINES; PROBIOTICS; PLACEBO; TRIAL; INFLAMMATION; DISORDERS; RECURRENT;
D O I
10.14309/ajg.0000000000002412
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
INTRODUCTION: There is minimal evidence regarding the comparative effectiveness of individual antibiotics in the treatment of pouchitis. We sought to evaluate the comparative effectiveness of ciprofloxacin monotherapy, metronidazole monotherapy, and combination therapy (ciprofloxacin and metronidazole) in the treatment of an initial episode of pouchitis after ileal pouch-anal anastomosis for ulcerative colitis (UC). METHODS: We performed a retrospective cohort study in TriNetX, a global federated research network of electronic health records. Primary outcomes were failure of initial antibiotic therapy and the development of recurrent pouchitis in the first 12 months after an initial episode of pouchitis. One-to-one propensity score matching was performed for age, sex, race, primary sclerosing cholangitis, nicotine dependence, obesity, and previous exposure to tumor necrosis factor inhibitors between the cohorts. RESULTS: Among 271 patients who developed pouchitis (mean age at ileal pouch-anal anastomosis 35.8 years, male sex 57%) and were treated with ciprofloxacin, metronidazole, or combination therapy, 190 (70%) developed recurrent pouchitis. After propensity score matching, there was no significant difference in the odds of early relapse or nonresponse with ciprofloxacin compared with metronidazole monotherapy (adjusted odds ratio 0.56, 95% confidence interval 0.23-1.34) or when either monotherapy was compared with combination therapy. There was also no significant difference in odds of recurrent pouchitis when comparing patients treated with ciprofloxacin with metronidazole monotherapy (adjusted odds ratio 0.86, 95% confidence interval 0.40-1.84) or either monotherapy with combination therapy. DISCUSSION: In this retrospective cohort study, we demonstrated no significant difference in the real-world effectiveness of ciprofloxacin, metronidazole, or combination therapy for the initial episode of pouchitis.
引用
收藏
页码:1989 / 1996
页数:8
相关论文
共 34 条
[1]   Perioperative and Postoperative Management of Patients With Crohn's Disease and Ulcerative Colitis [J].
Barne, Edward L. ;
Lightner, Amy L. ;
Regueiro, Miguel .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (06) :1356-1366
[2]  
Barnes Edward L, 2022, Clin Gastroenterol Hepatol, V20, P2908, DOI 10.1016/j.cgh.2021.09.037
[3]   Creation of a Case-Finding Definition for Identifying Patients With Acute Pouchitis in Administrative Claims Data [J].
Barnes, Edward L. ;
Kochar, Bharati ;
Herfarth, Hans H. ;
Winter, Rachel W. ;
Long, Millie D. ;
Korzenik, Joshua R. ;
Quevedo, Silvia F. ;
Galanko, Joseph A. ;
Koruda, Mark ;
Kappelman, Michael D. ;
Sandler, Robert S. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (04) :842-+
[4]   Incidence, Risk Factors, and Outcomes of Pouchitis and Pouch-Related Complications in Patients With Ulcerative Colitis [J].
Barnes, Edward L. ;
Herfarth, Hans H. ;
Kappelman, Michael D. ;
Zhang, Xian ;
Lightner, Amy ;
Long, Millie D. ;
Sandler, Robert S. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (08) :1583-+
[5]   Very Early Pouchitis Is Associated with an Increased Likelihood of Chronic Inflammatory Conditions of the Pouch [J].
Esckilsen, Scott ;
Kochar, Bharati ;
Weaver, Kimberly N. ;
Herfarth, Hans H. ;
Barnes, Edward L. .
DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (07) :3139-3147
[6]   Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial [J].
Gionchetti, P ;
Rizzello, F ;
Venturi, A ;
Brigidi, P ;
Matteuzzi, D ;
Bazzocchi, G ;
Poggioli, G ;
Miglioli, M ;
Campieri, M .
GASTROENTEROLOGY, 2000, 119 (02) :305-309
[7]   High-dose probiotics for the treatment of active pouchitis [J].
Gionchetti, Paolo ;
Rizzello, Fernando ;
Morselli, Claudia ;
Poggioli, Gilberto ;
Tambasco, Rosi ;
Calabrese, Carlo ;
Brigidi, Patrizia ;
Vitali, Beatrice ;
Straforini, Giulia ;
Campieri, Massimo .
DISEASES OF THE COLON & RECTUM, 2007, 50 (12) :2075-2082
[8]  
Gionchetti P, 2012, ANN GASTROENTEROL, V25, P100
[9]   Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: Propensity matched research network analysis [J].
Hadi, Yousaf ;
Dulai, Parambir S. ;
Kupec, Justin ;
Mohy-Ud-Din, Nabeeha ;
Jairath, Vipul ;
Farraye, Francis A. ;
Kochhar, Gursimran S. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (02) :191-200
[10]   Efficacy of Paxlovid and Lagevrio for COVID-19 Infection in Patients With Inflammatory Bowel Disease: A Propensity-Matched Study [J].
Hashash, Jana G. ;
Desai, Aakash ;
Kochhar, Gursimran S. ;
Farraye, Francis A. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (03) :841-+